Phaseline

Companies › RhoVac APS

RhoVac APS: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RV001V
peptide cancer vaccine
–Phase 2Prostate Cancer Recurrent–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04114825RV001VPhase 2Prostate Cancer RecurrentOncologyApr 2022

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Newish Technology (Beijing) BrainChild Bio TVAX Biomedical Lukas Biomedical March Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.